EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer

Kojiro Omiya, Atsushi Oba, Kimitaka Tanaka, Naoki Miyazaki, Shimpei Otsuka, Katsuhisa Ohgi, Teiichi Sugiura, Ryuta Shintakuya, Kenjiro Okada, Kenichiro Uemura, So Yamaki, Daisuke Hashimoto und 17 weitere

JAMA Surgery · 01.08.2026 · 161 (8) · 805

DOI: 10.1001/jamasurg.2026.1810 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Surgery, erschienen am 01.08.2026. Verfasst von Kojiro Omiya und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, CA-19-9 Antigen, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Approximately 5% to 10% of patients with pancreatic cancer are carbohydrate antigen 19-9 (CA 19-9) nonexpressors (≤2 U/mL), predominantly due to the Lewis-negative phenotype, leaving them without established biomarkers for treatment monitoring despite the central role of biomarker assessment in modern pancreatic cancer management.

Objective

To evaluate Duke pancreatic monoclonal antigen type 2 (DUPAN-2) as a surrogate biomarker for monitoring treatment response in patients with CA 19-9 nonexpressor pancreatic cancer. Design, Setting, and Participants This cohort study included patients with resected pancreatic ductal adenocarcinoma from 9 Japanese academic centers between January 1, 2013, and December 31, 2019. Patients were classified as CA 19-9 nonexpressors (≤2 U/mL) or expressors (>2 U/mL). Median (IQR) follow-up was 55.3 (38.5-74.1) months for expressors and 51.1 (39.3-72.4) months for nonexpressors. Two analysis cohorts were defined among nonexpressors: those with postneoadjuvant DUPAN-2 measurements and those with postresection DUPAN-2 measurements. Data were analyzed from July 2024 to February 2026. Exposures DUPAN-2 levels after neoadjuvant therapy and after resection, with normal levels defined as ≤150 U/mL. Main Outcomes and Measures Overall survival (OS) and disease-free survival (DFS) calculated from the date of resection.

Results

Among 2418 patients (median [IQR] age, 70 [63-76] years; 1404 [58.1%] male), 185 (7.7%) were CA 19-9 nonexpressors and 2233 (92.3%) were expressors. Nonexpressors and expressors showed comparable OS (adjusted hazard ratio [HR], 1.10; 95% CI, 0.89-1.37). DUPAN-2 dynamics in nonexpressors mirrored CA 19-9 patterns in expressors, with comparable median (IQR) reductions (postneoadjuvant: −64.5% [−82.2 to −37.2] vs −67.1% [−89.0 to −25.9]; postresection: −71.4% [−84.4 to −48.8] vs −73.4% [−90.7 to −35.4]). Achieving normal DUPAN-2 levels (≤150 U/mL) after neoadjuvant therapy was associated with improved OS (adjusted HR, 0.26; 95% CI, 0.07-0.93) and DFS (adjusted HR, 0.15; 95% CI, 0.04-0.53). Similarly, normal postresection DUPAN-2 was associated with better OS (adjusted HR, 0.18; 95% CI, 0.06-0.55) and DFS (adjusted HR, 0.23; 95% CI, 0.08-0.64). Conclusions and Relevance In this cohort study, DUPAN-2 served as an effective surrogate biomarker for patients with CA 19-9 nonexpressor pancreatic cancer, with normal posttreatment levels associated with favorable outcomes. These findings suggest that routine DUPAN-2 monitoring may enable biomarker-guided treatment decisions for this previously unassessable subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCA-19-9 AntigenBiomarkers, TumorCarcinoma, Pancreatic DuctalAntigens, NeoplasmHumansFemaleMaleAgedMiddle AgedNeoadjuvant Therapy

Substanzen

CA-19-9 AntigenBiomarkers, TumorAntigens, Neoplasm

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
  • Division of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora.
  • Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Hokkaido, Japan.
  • Division of Data Science, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Zitieren

APA

Omiya, K., Oba, A., Tanaka, K., Miyazaki, N., Otsuka, S., Ohgi, K., Sugiura, T., Shintakuya, R., Okada, K., Uemura, K., Yamaki, S., Hashimoto, D., Inoue, K., Mizuma, M., Unno, M., Nakagawa, N., Tanaka, H., Takami, H., Takeuchi, S., …, & Satoi, S. (2026). Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. JAMA Surgery, 161(8), 805. https://doi.org/10.1001/jamasurg.2026.1810

Vancouver

Omiya K, Oba A, Tanaka K, Miyazaki N, Otsuka S, Ohgi K, et al. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. JAMA Surgery. 2026;161(8):805. doi:10.1001/jamasurg.2026.1810

BibTeX
@article{Omiya2026,
  author = {Omiya, Kojiro and Oba, Atsushi and Tanaka, Kimitaka and Miyazaki, Naoki and Otsuka, Shimpei and Ohgi, Katsuhisa and Sugiura, Teiichi and Shintakuya, Ryuta and Okada, Kenjiro and Uemura, Kenichiro and Yamaki, So and Hashimoto, Daisuke and Inoue, Koetsu and Mizuma, Masamichi and Unno, Michiaki and Nakagawa, Nobuhiko and Tanaka, Haruyoshi and Takami, Hideki and Takeuchi, Shintaro and Ito, Akira and Akahoshi, Keiichi and Ban, Daisuke and Sugawara, Shuichiro and Takahashi, Ryosuke and Motoi, Fuyuhiko and Inoue, Yosuke and Takahashi, Yu and Hirano, Satoshi and Satoi, Sohei},
  title = {Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {8},
  pages = {805},
  doi = {10.1001/jamasurg.2026.1810}
}
Kostenlos starten →